Your browser doesn't support javascript.
loading
Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features.
Dejima, Hitoshi; Hu, Xin; Chen, Runzhe; Zhang, Jiexin; Fujimoto, Junya; Parra, Edwin R; Haymaker, Cara; Hubert, Shawna M; Duose, Dzifa; Solis, Luisa M; Su, Dan; Fukuoka, Junya; Tabata, Kazuhiro; Pham, Hoa H N; Mcgranahan, Nicholas; Zhang, Baili; Ye, Jie; Ying, Lisha; Little, Latasha; Gumbs, Curtis; Chow, Chi-Wan; Estecio, Marcos Roberto; Godoy, Myrna C B; Antonoff, Mara B; Sepesi, Boris; Pass, Harvey I; Behrens, Carmen; Zhang, Jianhua; Vaporciyan, Ara A; Heymach, John V; Scheet, Paul; Lee, J Jack; Wu, Jia; Futreal, P Andrew; Reuben, Alexandre; Kadara, Humam; Wistuba, Ignacio I; Zhang, Jianjun.
Afiliación
  • Dejima H; Department of Translational Molecular Pathology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Hu X; Department of Genomic Medicine, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Chen R; Department of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Zhang J; Department of Bioinformatics & Computational Biology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Fujimoto J; Department of Translational Molecular Pathology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Parra ER; Department of Translational Molecular Pathology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Haymaker C; Department of Translational Molecular Pathology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Hubert SM; Department of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Duose D; Department of Translational Molecular Pathology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Solis LM; Department of Translational Molecular Pathology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Su D; Institute of Cancer and Basic Medicine (IBMC), Chinese Academy of Sciences, Hangzhou, China.
  • Fukuoka J; Department of Pathology, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.
  • Tabata K; Department of Pathology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
  • Pham HHN; Department of Pathology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
  • Mcgranahan N; Department of Pathology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
  • Zhang B; Cancer Research United Kingdom-University College London Lung Cancer Centre of Excellence, London, UK.
  • Ye J; Department of Translational Molecular Pathology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Ying L; Department of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Little L; Institute of Cancer and Basic Medicine (IBMC), Chinese Academy of Sciences, Hangzhou, China.
  • Gumbs C; Zhejiang Cancer Research Institute, Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, China.
  • Chow CW; Department of Genomic Medicine, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Estecio MR; Department of Genomic Medicine, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Godoy MCB; Department of Translational Molecular Pathology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Antonoff MB; Department of Epigenetics and Molecular Carcinogenesis, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Sepesi B; Center of Cancer Epigenetics, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Pass HI; Department of Thoracic Imaging, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Behrens C; Department of Thoracic and Cardiovascular Surgery, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Zhang J; Department of Thoracic and Cardiovascular Surgery, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Vaporciyan AA; Department of Cardiothoracic Surgery, New York University Langone Medical Center, New York, NY, USA.
  • Heymach JV; Department of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Scheet P; Department of Genomic Medicine, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Lee JJ; Department of Thoracic and Cardiovascular Surgery, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wu J; Department of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Futreal PA; Department of Epidemiology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Reuben A; Department of Biostatistics, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Kadara H; Department of Thoracic/Head and Neck Medical Oncology, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wistuba II; Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Zhang J; Department of Genomic Medicine, the University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nat Commun ; 12(1): 2722, 2021 05 11.
Article en En | MEDLINE | ID: mdl-33976164
The mechanism by which anti-cancer immunity shapes early carcinogenesis of lung adenocarcinoma (ADC) is unknown. In this study, we characterize the immune contexture of invasive lung ADC and its precursors by transcriptomic immune profiling, T cell receptor (TCR) sequencing and multiplex immunofluorescence (mIF). Our results demonstrate that anti-tumor immunity evolved as a continuum from lung preneoplasia, to preinvasive ADC, minimally-invasive ADC and frankly invasive lung ADC with a gradually less effective and more intensively regulated immune response including down-regulation of immune-activation pathways, up-regulation of immunosuppressive pathways, lower infiltration of cytotoxic T cells (CTLs) and anti-tumor helper T cells (Th), higher infiltration of regulatory T cells (Tregs), decreased T cell clonality, and lower frequencies of top T cell clones in later-stages. Driver mutations, chromosomal copy number aberrations (CNAs) and aberrant DNA methylation may collectively impinge host immune responses and facilitate immune evasion, promoting the outgrowth of fit subclones in preneoplasia into dominant clones in invasive ADC.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Lesiones Precancerosas / Transcriptoma / Carcinogénesis / Adenocarcinoma in Situ / Adenocarcinoma del Pulmón / Neoplasias Pulmonares / Proteínas de Neoplasias Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Lesiones Precancerosas / Transcriptoma / Carcinogénesis / Adenocarcinoma in Situ / Adenocarcinoma del Pulmón / Neoplasias Pulmonares / Proteínas de Neoplasias Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido